Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Hepatitis C virus (HCV) infection is a major cause of chronic liver disease.
• Hypervariable region 1 (HVR1) of the HCV E2 envelope protein is a target for neutralizing antibodies.
• The role of cross-reactive antibodies against HVR1 in HCV disease progression remains unclear.

Purpose of the Study:

• To evaluate the presence and cross-reactivity of antibodies against HCV HVR1.
• To determine the relationship between HVR1 antibody cross-reactivity and HCV disease progression.

Main Methods:

• Sera from 55 chronic HCV patients (mild hepatitis, chronic hepatitis, liver cirrhosis) were analyzed.
• Sixteen representative HVR1 proteins were used to semiquantitate antibody cross-reactivity.
• Cross-reactivity was assessed in relation to clinical parameters like age, infection time, and liver enzyme levels.

Main Results:

• The degree of HVR1 antibody cross-reactivity was significantly higher in patients with chronic hepatitis and liver cirrhosis compared to those with mild hepatitis.
• No correlation was found between antibody cross-reactivity breadth and patient age, infection duration, ALT, or HCV-RNA levels.
• The breadth of HVR1 antibody cross-reactivity, not just its presence, was associated with liver disease progression.

Conclusions:

• Broadly cross-reactive HVR1 antibodies in HCV patients do not neutralize the virus.
• These antibodies contribute to persistent HCV infection in patients with chronic hepatitis.
• The findings highlight the complex interplay between viral evolution and host immune response in HCV pathogenesis.